Text Box: THE CHILDREN WITH CHOLESTASE SYNDROM (CS): TREATMENT OF CHRONIC HEPATITIS ¡°B¡± (CH¡±B¡±) COMBINED WITH THE URSODESOXIHOLIC ACID (UDHA) AND a2B-INTERFERON KADYROV BAKHTIOR Tashkent, Uzbekistan Objective: To increase the efficiency of immuno-correcting therapy for children with hepatisis ¡°B¡± and cholestase syndrom. Methods: It is known that the high bilirubin and bile acids level in blood has significant immuno-supressive impact and decrease the efficiency of immuno-correcting therapy. 30 children from 5 to 12 years with the disease duration more than 2 years had been split for 2 groups: 10 children and 20. 1st group was receiving 3 mln a2B-I during 6 months, 2nd group had additionally been given UDHA until the CS is eliminated. Treatment efficiency has been assessed based upon the activities of cholestase, state of the cell-mediated immunity and dynamics of the marker profile. The CS has been observed at the 1/3 children of the 1st group for entire course of treatment, in the 2nd group the positive dynamics has been observed at more than half of the patients by the 2nd month of curing. By the 3rd month the activities of the cell-mediated immunity were getting significantly better at the 4 children from the 1st group and 16 children of the 2nd group. By that time the sulfur conversion HBeAq on the antiHBe has been observed at the 7 children from the 1st group and 18 children of the 2nd group. Conclusion: Significant efficiency of the combined treatment for CH¡±B¡± with CS is testified by the high frequency of immune and virological response and the percent decrease in exacerbation. 1996